Suresh Sureddi, MD
Psychiatry · Plano, TXNPI 1710932561
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,697,909 of the $2,175,157 with a category attached, or 78.1%. 21 manufacturers reported payments, led by Alkermes, Inc. at 25.8% of the total. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,730 payments — averaging $796.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$562K
- Otsuka America Pharmaceutical, Inc.$339K
- Neurocrine Biosciences, Inc.$332K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$291K
- Axsome Therapeutics, Inc.$250K
- AbbVie$190K
- plus $211K from 15 others
Across 207 payments — averaging $17,818 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$2.1M
- E.r. Squibb & Sons, L.L.C.$908K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$486K
- Boehringer Ingelheim$152K
- Sage Therapeutics, LLC$27K
- Boehringer Ingelheim RCV GmbH & Co KG$12K
- plus $1K from 1 others
What the payments were for
- Consulting fees$215,91210%
- Speaking & faculty fees$1,697,90978%
- Travel & lodging$212,37610%
- Food & beverage$48,7832%
- Education$1770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 747 | $562,272 |
| Otsuka America Pharmaceutical, Inc. | 454 | $338,881 |
| Neurocrine Biosciences, Inc. | 321 | $331,583 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 288 | $291,460 |
| Axsome Therapeutics, Inc. | 243 | $250,282 |
| AbbVie(2 entities) | 230 | $190,143 |
| Teva Pharmaceuticals USA, Inc. | 207 | $156,390 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 24 | $19,297 |
| Janssen Research & Development, LLC | 11 | $8,265 |
| Sunovion Pharmaceuticals Inc. | 74 | $7,977 |
| H. Lundbeck A S | 3 | $7,010 |
| E.r. Squibb & Sons, L.L.C. | 49 | $6,206 |
| Johnson & Johnson(2 entities) | 44 | $3,942 |
| Vanda Pharmaceuticals Inc. | 6 | $806 |
| Jazz Pharmaceuticals Inc. | 5 | $267 |
| Tris Pharma Inc | 14 | $156 |
| Harmony Biosciences LLC | 3 | $90 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| Indivior Inc. | 2 | $38 |
| Lundbeck LLC | 2 | $35 |
| Evofem Biosciences, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,242,053
- LYBALVI$977,618
- ABILIFY MAINTENA$342,437
- INGREZZA$326,584
- ARISTADA INITIO$295,688
- CAPLYTA$286,685
- Auvelity$245,758
- VRAYLAR$186,695
- ABILIFY ASIMTUFII$163,269
- Austedo XR$94,295
- AUSTEDO$58,194
- LATUDA$6,758
- SPRAVATO$3,013
- Fanapt$698
- COBENFY$466
- REXULTI$264
- SUNOSI$127
- INVEGA SUSTENNA$103
How this compares
$2,175,157 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 32 | $277,649 |
| Abilify AsimtufiiAripiprazole | 22 | $103,633 |
| Abilify MaintenaAripiprazole | 34 | $95,786 |
| LybalviOlanzapine/Samidorphan Malate | 52 | $85,618 |
| Invega SustennaPaliperidone Palmitate | 20 | $69,379 |
| VraylarCariprazine Hcl | 26 | $38,498 |
| CaplytaLumateperone Tosylate | 21 | $33,654 |
| Lurasidone Hcl | 28 | $22,255 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $18,085 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 152 | $7,056 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $5,076 |
| Quetiapine Fumarate | 202 | $3,565 |
| Aripiprazole | 97 | $2,994 |
| Clonazepam | 226 | $2,503 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 34 | $2,072 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $331,583 | $277,64932 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Abilify Maintena | $338,881 | $199,42056 claims |
| Alkermes, Inc.Lybalvi | $562,272 | $85,61852 claims |
| Johnson & JohnsonInvega Sustenna | $3,942 | $69,37920 claims |
| AbbVieVraylar | $190,143 | $38,49826 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $291,460 | $33,65421 claims |
| Axsome Therapeutics, Inc.Auvelity | $250,282 | $18,08511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Plano
- David CrumpackerPlano$386K
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
- Alice MaoHouston$850K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.